BIOCEPT INC
DelistedCIK 1044378fmd_0NQZ7H02WYAAGY960HXRN6QGC8Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2023, 42 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 1 | 3 | 5 | 3 | 6 | 27 | 61 | 26 |
| Cost of revenue | 2 | 2 | 5 | 7 | 9 | 10 | 11 | 21 | 38 | 28 |
| Gross profit | (2) | (2) | (4) | (4) | (4) | (7) | (5) | 6 | 23 | (3) |
| Research and development | 3 | 4 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 6 |
| Selling, general and administrative | 3 | 7 | 10 | 12 | 14 | 13 | 13 | 16 | 21 | 23 |
| Operating income | (8) | (14) | (16) | (18) | (21) | (24) | (23) | (15) | (2) | (32) |
| Interest expense | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (1) | (2) | (1) | (0) | (0) | (0) | (2) | (2) | (0) | (0) |
| Income before taxes | (9) | (16) | (17) | (18) | (22) | (25) | (25) | (18) | (3) | (32) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | 0 | (0) |
| Net income from continuing operations | (9) | (16) | (17) | (18) | (22) | (25) | – | – | (3) | (32) |
| Net income | (9) | (16) | (17) | (18) | (22) | (25) | (25) | (18) | (3) | (32) |
| Net income to common shareholders | – | – | – | – | (22) | (25) | (25) | (18) | (3) | (32) |